September 25, 2015: Resverlogix clinical and science teams, along with two members of the international clinical steering committee for the upcoming BETonMACE study, presented a Research and Development Update for RVX-208 "apabetalone" on September 25, 2015 in New York City. Please access the replay here: http://services.choruscall.ca/links/resverlogix150929.html
Sept. 10, 2015: Donald McCaffrey presented at the Rodman & Renshaw 17th Annual Global Investment Conference. Link to presentation: http://wsw.com/webcast/rrshq25/register.aspx?conf=rrshq25&page=rvx&url=http://wsw.com/webcast/rrshq25/rvx/index.aspx
Resverlogix in the Media
Aug. 26, 2015: Resverlogix featured in the Life Sciences Report: Disrupting Treatment of Cardiovascular Disease with Epigenetics: Resverlogix CEO Donald McCaffrey. Access article here: /upload/media_element/218/01/donald-mccaffrey-lsr-interview-8-26-15.pdf
June 25, 2015: Resverlogix’s Dr. Ewelina Kulikowski has written and published an article for the summer 2015 issue of the European Biopharmaceutical Review (EBR) titled, “New Direction.” Access article here: http://www.resverlogix.com/upload/media_element/213/01/ebr_july-15_pp.76-79-resverlogix-corp.pdf
April 22, 2015: Donald McCaffrey, President & CEO on BNN’s Business Day
April 27, 2015- BioCentury: Hepalink gains rights to Resverlogix’s RVX-208 in China. Link here: http://www.biocentury.com/dailynews/company/2015-04-27/hepalink-gains-rights-to-resverlogixs-rvx-208-in-china
April 28, 2015- BioWorld Today: Phase III Starting Soon. Resverlogix getting specific: With potential $400M BET, Hepalink licensing accord, by Randy Osborne. Link here to access the full article.
April 28, 2015- Bloomberg Business: Resverlogix in Discussions to Be Bought, by Eric Lam. Link here: http://www.bloomberg.com/news/articles/2015-04-28/resverlogix-ceo-says-company-in-discussions-to-be-bought
April 28, 2015- BioSpace Breaking News: Resverlogix (RVX.TO) CEO Says It’s in Talks With Suitors, After $100M in Q1 Deals, by Riley McDermid. Link here: http://www.biospace.com/News/with-almost-a-100-million-in-deals-for-q1/374186?source=sm&type=twitter_resverlogix042815
April 28, 2015- Fierce Biotech: Resverlogix gets a $116M China Drug development deal, stokes buyout buzz, by John Carroll. Link here: http://www.fiercebiotech.com/story/resverlogix-gets-116m-china-drug-development-deal-stokes-buyout-buzz/2015-04-28
April 28, 2015 - GEN News Highlights: Hepalink Buys China-Area Rights to Resverlogix's CV Candidate for Up-to-$441.5M Link here: http://www.genengnews.com/gen-news-highlights/hepalink-buys-china-area-rights-to-resverlogix-s-cv-candidate-for-up-to-441-5m/81251205/
Events - July to September 2015
Resverlogix will be attending several key industry conferences. Not all events offer a presentation opportunity. Please note this list is not exhaustive and subject to change.
Alzheimer's Association Research Roundtable (AAIC) 2015, Washington, DC, July 18-23.
EpiCongress Boston 2015, Boston, MA, July 22-24.
European Society of Cardiology (ESC) Congress 2015, London, England, August 29 - Sept. 2.
17th Annual Global Investment Conference Rodman & Renshaw 2015, New York City, NY, Sept. 8-10.
51st Annual European Association for the Study of Diabetes (EASD), Stockholm, Sweden, Sept.14-18.
GCFF Investment Conference,Toronto, ON, Sept. 26.
Resverlogix Annual General Meeting (AGM), Calgary, AB, Sept. 30.